Digital Health: Does Pharma Need To Change Its Business Model To Make It Work?
This article was originally published in Scrip
Executive Summary
By 2020, pharmaceutical business models will be turned on their head because of digital health, according to a new report by the management consultancy firm Arthur D. Little (ADL).
You may also be interested in...
When The Trial Site Is A Living Room: Pharma Explores Virtual Research Options
One day in the future, clinical studies may routinely be carried out in the virtual world, with patients mostly staying put at home instead of traveling to trial sites. For now, sponsors are experimenting with new models for drug development and taking it one step at a time.
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.